Topic

Articles

ABPI has asked for a temporary ban to be put in place on drug exports by wholesalers to protect the National Health Service (NHS) from potential shortages in a ‘no-deal’ Brexit scenario.

Difficult to Swallow? ABPI Requests Temporary Ban on Drug Exports Amid Fears of a ‘No-Deal’ Brexit

The agency has published a Q&A document to answer questions about what EMA is doing to prevent medicine shortages during Brexit.

EMA Answers Brexit Questions

Brexit update: The UK government has rejected the withdrawal deal again and now faces further uncertainty, despite rejections of a 'no-deal' scenario by ministers, as well as a high probability of Brexit delay.

Thrice into the Fray: UK PM Asks Government to Vote on Brexit Deal for a Third Time

A new survey, commissioned by the Royal Society of Chemistry, has highlighted the level of concern within the UK’s chemistry sector surrounding the potential ‘no-deal’ Brexit outcome.

Chemistry Professionals Overwhelmingly Concerned by ‘No-Deal’ Brexit, Notes Survey

The Regulatory Affairs Professional Society (RAPS) has unveiled the details of its inaugural European regulatory conference, RAPS Regulatory Conference-Europe 2019.

RAPS Prepares to Hold its Inaugural European Regulatory Conference in May

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As we approach the next instalment of Pharmapack Europe, a potentially perilous situation in relation to drug packaging has emerged for pharmaceutical companies should Brexit result in a ‘no deal’ scenario.

Packaging Peril: ‘No-Deal’ Brexit May Lead to Missed Deadline

The ABPI has released a statement calling for action to address skills shortages in science within the UK, which could jeopardize the country’s position for medicines and vaccines R&D. 


ABPI Calls for Action to Plug Science Skills Gaps

The European Medicines Agency has announced that its physical relocation to Amsterdam will be complete in March 2019.

EMA Implements the Next Phase in its Relocation Plan

The Wasdell Group has been granted a Health Products Regulatory Authority (HPRA) license for its new European headquarters, based in Dundalk, Ireland.

Wasdell Group’s New EU HQ Receives HPRA License

Following the defeat of the UK's Prime Minister’s proposed Brexit withdrawal deal, substantial uncertainty around Brexit remains and risks to public heath and the economy are mounting.

Bio/Pharma and Brexit